Tectonic Therapeutics Conference Call Summary Company Overview - **Company**: Tectonic Therapeutics (NasdaqGM: TECX) - **Focus**: Development of a pipeline of agonists and antagonists against GPCRs (G-protein-coupled receptors) [5][69] Key Programs TX45 - **Description**: Long-acting relaxin in clinical studies for Group 2 pulmonary hypertension - **Clinical Studies**: Two ongoing studies, with Phase 2 APEX study results expected in late 2026 or early 2027 [5][8] - **Patient Population**: Focus on stable, euvolemic patients to mitigate risks of fluid retention seen in previous studies [12][41] - **Dosing**: Every four weeks, with a target of 300 mg [34][35] - **Expected Outcomes**: A 15%-20% reduction in pulmonary vascular resistance (PVR) and improvement in hemodynamic measures [42] TX2100 - **Description**: APJ antagonist for Hereditary Hemorrhagic Telangiectasia (HHT) - **Current Status**: Phase 1 study in normal healthy volunteers, with data expected later this year [6][7] - **Mechanism**: Selective anti-angiogenic agent targeting upregulated angiogenesis in HHT [59] Competitive Landscape - **Lilly and AstraZeneca**: Recent failures in relaxin candidates due to patient population and dosing issues [9][10][12] - **Differentiation**: TX45 has a lower isoelectric point, leading to better pharmacokinetics compared to competitors [28][29] - **Patient Selection**: Tectonic's strategy includes enriching for patients with higher PVR, which may enhance efficacy [39][41] Industry Insights - **Challenges in PH-ILD**: Previous vasodilators have failed due to V/Q mismatch; Tectonic aims to address this with relaxin [50][51] - **Antifibrotic Effects**: Potential benefits of relaxin in reducing pulmonary artery pressure and vascular resistance [47][48] Future Development - **PH-ILD Study**: Recently initiated, with a primary endpoint of PVR reduction; data expected around 2027 [57] - **GEODe™ Platform**: Proprietary platform for developing biologics against GPCRs, with future pipeline candidates anticipated [68][69] Conclusion - Tectonic Therapeutics is positioned to leverage its unique drug candidates and proprietary platform to address significant unmet needs in pulmonary hypertension and related conditions, with a focus on differentiated mechanisms and patient populations.

Company Overview - Tectonic Therapeutics is focused on the discovery and development of both agonist and antagonist biologics targeting GPCRs (G protein-coupled receptors) [2] - The executive team has extensive experience, having led teams that resulted in over 20 first approvals of drugs and numerous follow-up indications [2] Product Pipeline - Tectonic has a robust product pipeline aimed at high unmet need areas with multibillion-dollar market potential [2] - Currently, the company has 2 programs in the clinic covering 3 indications, along with a strong emerging preclinical pipeline [3] - One of the key programs is TX45, a long-acting relaxin, which is in Phase II for pulmonary hypertension associated with preserved ejection fraction and heart failure [3]

Core Insights - Tectonic Therapeutic, Inc. reported significant advancements in its clinical pipeline, including the initiation of clinical trials for TX2100 and TX45, targeting high unmet medical needs in patients with Hereditary Hemorrhagic Telangiectasia (HHT) and pulmonary hypertension [2][4][10] Recent Business Highlights - The company advanced TX2100 into a Phase 1a clinical trial, marking a milestone with the first patient dosed in February 2026 [2][4] - TX45 showed positive topline results in a Phase 1b trial for Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (PH-HFrEF), demonstrating a 29.2% reduction in pulmonary capillary wedge pressure and a 17.3% improvement in cardiac output [5] - Tectonic initiated a Phase 2 clinical trial for TX45 in patients with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) in February 2026 [4][5] - The company appointed François Nader, M.D., MBA, as an independent director and Chair of the Board, effective April 1, 2026 [4] Financial Overview - As of December 31, 2025, Tectonic had cash and cash equivalents of approximately $253.8 million, expected to sustain operations into Q4 2028 [4][10] - Research and development expenses for Q4 2025 were $16.3 million, up from $9.2 million in Q4 2024, primarily due to increased clinical trial costs [10] - The net loss for Q4 2025 was $19.2 million, compared to a net loss of $12.4 million in Q4 2024 [10][19] Upcoming Milestones - Topline results for the TX2100 Phase 1a clinical trial are expected in Q4 2026, with plans for a Phase 2 trial in early 2027 [10] - Topline results from the TX45 APEX Phase 2 clinical trial are anticipated in 2026, focusing on patients with PH-HFpEF [10]

Core Insights - Tectonic Therapeutic, Inc. (NASDAQ:TECX) is recognized as one of the best micro-cap stocks to invest in according to analysts [1] - LifeSci Capital has reiterated a Buy rating on TECX with a price target of $88, indicating strong confidence in the stock's potential [2] Company Overview - Tectonic Therapeutic is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCRs) [2][3] - The company has developed the GEODe technology platform to facilitate the discovery and development of GPCR-targeted biologic medicines [3] Product Pipeline - One of the lead product candidates is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, which is the GPCR target of the hormone relaxin [3] - Tectonic is also developing TX2100, aimed at treating hereditary hemorrhagic telangiectasia, and other GPCR modulators for treating fibrosis and related conditions [3]

Summary of Tectonic Therapeutic FY Conference Call Company Overview - **Company**: Tectonic Therapeutic (NasdaqGM: TECX) - **Event**: FY Conference on December 02, 2025 Key Industry Insights - **Focus**: The conference highlighted the significance of the APEX study, which is expected to be pivotal for Tectonic in 2026, marking the beginning of a critical two-year period for the company [1][2] Core Points and Arguments 1. **Enrollment Progress**: - Tectonic met its mid-year recruitment objectives and is on track to meet its end-of-year recruitment goal. As of November, recruitment has shifted to patients with a pulmonary vascular resistance (PVR) greater than three [4][5] - 70% of the total patient population falls within the PVR greater than three category [11][13] 2. **Data Safety Monitoring**: - The last data safety monitoring committee (DSMB) meeting occurred at the end of September, with no safety signals reported. Continuous monitoring is in place [5][6] 3. **Patient Population and Study Design**: - The study is enriched for patients with chronic stable heart failure and high PVR, aiming to improve outcomes in this specific group [30][34] - The primary endpoint focuses on PVR reduction, with a previous phase 1b study showing a 30% decrease in PVR [23][24] 4. **Comparison with Competitors**: - Tectonic's TX45 is differentiated from competitors like AstraZeneca and Lilly based on patient selection and study design. Tectonic's study focuses on a more homogeneous population with specific PVR criteria [30][37] - The mechanism of action for TX45 includes vasodilation and potential antifibrotic effects, which may provide advantages over competitors [39][41] 5. **Future Development Plans**: - Tectonic is considering various options for future studies in heart failure with preserved ejection fraction (HFpEF), including standalone phase 2 or phase 2/3 studies [29][30] - The company plans to start a healthy volunteer study for TX2100 in early 2026, focusing on pharmacokinetics and safety [47] Other Important Information - **Financial Position**: Tectonic reported approximately $268 million in cash, providing a runway into the fourth quarter of 2028 [49] - **Market Context**: The discussion emphasized the complexity of the heart failure market, with multiple mechanisms and treatment options available, indicating a significant opportunity for Tectonic's therapies [43][44]

Group 1 - The article discusses Tectonic Therapeutic, Inc. (TECX) and its potential expansion of the TX45 candidate following positive interim data [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and runs the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies [2] - The Biotech Analysis Central service includes a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2] Group 2 - The article does not provide any specific financial data or performance metrics related to Tectonic Therapeutic, Inc. or the biotech industry [1][3][4]

Core Insights - The conference call focuses on the top line results from Part B of the Phase Ib clinical trial evaluating TX45 for patients with pulmonary hypertension associated with reduced ejection fraction heart failure (PH-HFrEF) [2][3] Group 1: Clinical Trial Overview - The clinical trial involved 14 patients and aimed to assess the safety and tolerability of TX45 in the PH-HFrEF patient population [3] - The trial also sought to explore the hemodynamic effects of TX45, with expectations of observing effects similar to previous studies [3]

Summary of Tectonic Therapeutic (NasdaqGM:TECX) Conference Call on TX45 Phase 1B Part B Results Company Overview - **Company**: Tectonic Therapeutic - **Product**: TX45 - **Focus**: Treatment for pulmonary hypertension associated with reduced ejection fraction heart failure (PHFREF) Key Points from the Conference Call Clinical Trial Results - **Trial Design**: Phase 1B clinical trial evaluated safety and hemodynamic effects of TX45 in 14 patients with PHFREF [2][3] - **Primary Endpoint**: Mean change from baseline in pulmonary vascular resistance (PVR) for patients with PVR ≥ 3 WU [4] - **Results**: TX45 was well tolerated, showing improvements in all hemodynamic measurements evaluated [3][12] - **Wedge Pressure**: Decreased by over 6 mmHg, translating to a 29% reduction from baseline [13] - **PVR Reduction**: Approximately 20% reduction in PVR for patients with PVR ≥ 3 WU [14] - **Cardiac Output**: Increased by approximately 17% [16] - **Mean Pulmonary Artery Pressure**: Decreased by 19% [16] - **Ejection Fraction Improvement**: Left ventricular ejection fraction improved from 34% at baseline to 40.3% at day 29, representing a 19% increase [17] Market Potential - **Patient Population**: Approximately 1.1 million people in the U.S. with PHFREF, with around 300,000 having CPCPH and PVR ≥ 3 [6] - **Need for Treatment**: Significant need for new treatments due to worse exercise capacity and increased mortality in patients with pulmonary hypertension [5] Future Clinical Trials - **APEX Phase 2 Trial**: Ongoing trial with over 50% enrollment, focusing on patients with PVR ≥ 3 WU [21] - **Upcoming Studies**: Plans to initiate a study for TX45 in pulmonary hypertension associated with interstitial lung disease (PHILD) [22] - **Financial Health**: Company has a financial runway into Q4 2028 [22] Safety and Tolerability - **Adverse Events**: No serious or severe adverse events reported; only mild to moderate procedure-related back pain observed [12] - **Vital Signs**: No clinically significant changes in vital signs, ECG, or lab values [12] Discussion Points - **Correlation with Exercise Capacity**: Data suggests that improvements in hemodynamics may correlate with increased exercise tolerance, although exact predictions for 6-minute walk tests remain uncertain [20] - **Data Consistency**: Consistency of results across different patient populations was noted, reinforcing confidence in TX45's efficacy [23][26] Regulatory and Development Considerations - **Future Steps**: Potential for a Phase 2/3 trial for HFREF, depending on APEX trial results and regulatory alignment [57] Additional Insights - **Echocardiographic Data**: Persistent improvements in left ventricular function and pulmonary hemodynamics observed up to 29 days post-dose [17][19] - **Outlier Impact**: Discussion on the impact of an outlier patient on mean and median hemodynamic results, highlighting variability in small sample sizes [33][34] This summary encapsulates the critical findings and future directions for Tectonic Therapeutic's TX45, emphasizing its potential impact on treating PHFREF and the company's strategic plans moving forward.

Trial Results - TX45 was well-tolerated in patients with PH-HFrEF in a single-dose study[6, 17] - The trial observed improvements in left ventricular function and pulmonary hemodynamics in PH-HFrEF, consistent with effects demonstrated in the PH-HFpEF study[6, 23] - In PH-HFrEF patients, TX45 led to a mean reduction of 64 mm Hg (292%) in PCWP (Pulmonary Capillary Wedge Pressure)[18] - In CpcPH patients (PVR ≥ 3 WU), TX45 resulted in a mean reduction of 110 WU (197%) in PVR (Pulmonary Vascular Resistance)[18] - Cardiac Output (CO) increased by a mean of 065 L/min (173%) in all participants[18] - Stroke Volume (SV) increased by a mean of 68 mL (134%) in all participants[18] - Total Pulmonary Resistance (TPR) decreased by a mean of 282 WU (292%) in all participants[18] - Mean Pulmonary Artery Pressure (mPAP) decreased by a mean of 65 mm Hg (193%) in all participants[18] - Systemic Vascular Resistance (SVR) decreased by a mean of 32 WU (129%) in all participants[18] - Right Atrial Pressure (RAP) decreased by a mean of 31 mm Hg (292%) in all participants[18] Market Opportunity - The potential market for PH-HFrEF in the US is approximately 11 million, with about 300,000 cases of CpcPH (PVR≥3)[7]

Core Insights - Tectonic Therapeutic, Inc. announced positive topline results from the Phase 1b Part B clinical trial of TX45, showing significant improvements in left heart function and pulmonary hemodynamics in patients with Group 2 PH-HFrEF [1][4][8] Clinical Trial Overview - The Phase 1b Part B trial evaluated TX45 in an expanded patient population of Group 2 PH-HFrEF, building on previous positive results from the Phase 1b Part A trial in Group 2 PH-HFpEF [2][3] - The ongoing APEX Phase 2 clinical trial aims to assess TX45 over a 24-week treatment period in patients with PH-HFpEF, with topline results expected in 2026 [2] Hemodynamic Results - TX45 administration led to meaningful improvements in hemodynamic measures, including a 29.2% reduction in pulmonary capillary wedge pressure (PCWP) and a 17.3% increase in cardiac output (CO) [7][9] - Other significant changes included a 19.3% decrease in mean pulmonary artery pressure (mPAP) and a 29.2% reduction in total pulmonary resistance (TPR) [9] Safety and Tolerability - TX45 was well tolerated among patients with no serious or severe adverse events reported, and no clinically significant changes in blood pressure or immune-related reactions were observed [8][11] Echocardiography Results - Echocardiography data indicated persistent improvements in left and right ventricular function and pulmonary hemodynamics at 29 days post-dose [10][12] Future Directions - The results from the Phase 1b Part B trial open the potential for TX45 to address significant unmet needs in the PH-HFrEF patient population, pending further results from the APEX Phase 2 trial [3][12]